Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 05:49 am
Share
Hunan Er-Kang Pharmaceutical Co., Ltd reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 1,581.33 million compared to CNY 1,781.29 million a year ago. Revenue was CNY 1,581.33 million compared to CNY 1,781.29 million a year ago. Net income was CNY 156.48 million compared to CNY 181.4 million a year ago. Basic earnings per share from continuing operations was CNY 0.0759 compared to CNY 0.0882 a year ago. Diluted earnings per share from continuing operations was CNY 0.0759 compared to CNY 0.0882 a year ago.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD 
